Duration not severity of the climacteric syndrome predicts resumption of hormone therapy after discontinuation: A prospective cohort study

Human Reproduction

Volumn 21, Issue 9, 2006, Pages 2450-2454

  Haimov Kochman, Ronit ^b   Barak Glantz, Edyah ^a   Ein Mor, Eliana ^a   Arbel, Revital ^a   Brzezinski, Amnon ^a   Milwidsky, Ariel ^a   Hochner Celnikier, Drorith ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Discontinuation; Hormone therapy; Hot flashes; Menopause; Predictors

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CLINICAL PROTOCOL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE DURATION; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; MONOTHERAPY; PATIENT MONITORING; PREVALENCE; PROSPECTIVE STUDY; RATING SCALE; SCORING SYSTEM;

EID: 33749562318     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/del191     Document Type: Article

References (13)

1. Ettinger B, Grady D, Tosteson AN, Pressman A and Macer JL (2003) Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 102,1225-1232.
2. Freedman RR (2001) Physiology of hot flashes. Am J Hum Biol 13,453-464.
3. Grady D, Ettinger B, Tosteson AN, Pressman A and Macer JL (2003) Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 102,1233-1239.
4. Greene JG (1998) Constructing a standard climacteric scale. Maturitas 29,25-31.
5. Haimov-Kochman R, Barak-Glantz E, Arbel R, Leefsma M, Brzezinski A, Milwidsky A and Hochner-Celnikier D (in press) Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms. A randomized prospective study. Menopause.
6. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H et al. (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 288,58-66.
7. Li C, Samsioe G, Lidfelt J, Nerbrand C and Agardh CD, Women's Health in Lund Area (WHILA) Study (2000). Important factors for use of hormone replacement therapy: A population-based study of Swedish women. The Women's Health Lund Area (WHILA) Study. Menopause 7,273-281.
8. Ness J, Aronow WS and Beck G (2006) Menopausal symptoms after cessation of hormone replacement therapy. Maturitas 53,356-361.
9. North American Menopause Society (2002). NAMS Advisory Panel on Report from the Postmenopausal Hormone Therapy. Menopause, October (http://www.menopause.org/news.html#advisory).
10. Ockene JK, Barad DH, Cochrane BB, Larson JC, Gass M, Wassertheil-Smoller S, Manson JE, Barnabei VM, Lane DS, Brzyski RG et al. (2005) Symptom experience after discontinuing use of estrogen plus progestin. JAMA 294,183-193.
11. Rolnick SJ, Kopher RA, DeFor TA and Kelley ME (2005) Hormone use and patient concerns after the findings of the Women's Health Initiative. Menopause 12,399-404.
12. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN III, Assaf AR, Jackson RD et al. (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's HealAh Initiative Memory Study: a randomized controlled trial. JAMA 289,2651-2662.
13. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288,321-333.